medscape.com
Cure8 news brief
Why This Matters
This study suggests risankizumab may improve quality of life and reduce common symptoms (fatigue, mood, urgency) more than ustekinumab for patients with moderate-to-severe Crohn’s disease who didn’t respond to anti-TNF drugs. QOL and patient-reported outcomes are central to treatment goals.
Who Should Pay Attention
Adult patients with moderate-to-severe Crohn's disease, especially those who failed anti-TNF therapy; clinicians making biologic treatment decisions; researchers interested in comparative biologic effects on patient-reported outcomes.
Study Snapshot
Story typeResearch news
Evidence typePhase 3 clinical trial
Source depthFull source text
What To Know
The analysis compared recommended induction and maintenance regimens of risankizumab versus ustekinumab in 520 patients previously unresponsive to anti-TNF therapy.
More patients on risankizumab reached IBDQ response and remission and meaningful within-person improvements in physical and mental component scores of the SF-36v2, with differences reported at both 24 and 48 weeks. Study context: The trial was open-label and funded by AbbVie; several authors had financial ties to the company.
The authors note limitations including open-label design, higher discontinuation in the ustekinumab group, and that the population was limited to anti-TNF nonresponders, which affects generalizability.
Practical note: This article summarizes a post hoc comparison focusing on patient-reported quality-of-life outcomes rather than head-to-head clinical efficacy endpoints; discuss individual treatment choices and applicability with your treating clinician.
Keep In Mind
The analysis is post hoc from an open-label phase 3b trial funded by AbbVie; patient-reported outcomes can be influenced by study design and discontinuation rates. Results apply specifically to patients with prior anti-TNF failure and may not generalize to biologic-naive populations.
Source Details
Review the original publication for the complete reporting, methods, and context.
Phase 3 clinical trial
Article type assigned from Cure8 classification; confirm details in the original source.
Publicationmedscape.com
Indexed viaGoogle News
Source typeResearch news
PublishedJun 18, 2026, 10:12 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Real-World Data Show Efficacy of Risankizumab in Refractory Crohn's
This study reports real-world effectiveness of risankizumab for refractory Crohn's disease, showing many patients achieved steroid-free remission. The results are relevant for people weighing treatment options after...
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...